Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.

Macarena I de la Fuente,Howard Colman,Mark Rosenthal,Brian A Van Tine, Danijela Levacic,Tobias Walbert,Hui K Gan,Maria Vieito,Mohammed M Milhem,Kathryn Lipford,Sanjeev Forsyth,Sylvie M Guichard, Yelena Mikhailov, Alexander Sedkov,Julie Brevard,Patrick F Kelly,Hesham Mohamed,Varun Monga

Neuro-oncology（2023）

引用 16|浏览25

暂无评分

摘要

Olutasidenib 150 mg BID was well tolerated in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation and demonstrated preliminary evidence of clinical activity in this heavily pretreated population.

查看译文

关键词

IDH1,brain penetration,glioma,mutant,olutasidenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要